HC Wainwright Has Negative Estimate for Oculis Q1 Earnings

Oculis Holding AG (NASDAQ:OCS) – Research analysts at HC Wainwright lowered their Q1 2026 EPS estimates for Oculis in a research report issued to clients and investors on Wednesday, March 4th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.47) for the quarter, down from their previous estimate of ($0.46). HC Wainwright has a “Buy” rating and a $44.00 price objective on the stock. The consensus estimate for Oculis’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Oculis’ Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.50) EPS and FY2026 earnings at ($1.95) EPS.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.08). Oculis had a negative net margin of 8,173.41% and a negative return on equity of 62.12%. The firm had revenue of $0.50 million during the quarter, compared to analyst estimates of $0.14 million.

A number of other analysts have also commented on the company. JPMorgan Chase & Co. began coverage on Oculis in a report on Friday, December 19th. They issued an “overweight” rating and a $38.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research report on Thursday, January 22nd. Stifel Nicolaus lifted their price objective on shares of Oculis from $40.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday. Bank of America cut their price objective on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. Finally, Chardan Capital restated a “buy” rating and set a $51.00 target price on shares of Oculis in a report on Tuesday, November 11th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $43.50.

Oculis Stock Down 2.8%

NASDAQ:OCS opened at $26.96 on Friday. Oculis has a 1 year low of $14.00 and a 1 year high of $30.68. The stock has a 50-day moving average price of $26.16 and a two-hundred day moving average price of $21.55. The stock has a market cap of $1.56 billion, a price-to-earnings ratio of -11.88 and a beta of 0.29. The company has a current ratio of 5.96, a quick ratio of 4.47 and a debt-to-equity ratio of 0.01.

Institutional Investors Weigh In On Oculis

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Perceptive Advisors LLC acquired a new stake in shares of Oculis in the 4th quarter valued at approximately $9,862,000. Millennium Management LLC acquired a new stake in Oculis during the 4th quarter valued at $312,000. NEXTBio Capital Management LP acquired a new stake in shares of Oculis during the 4th quarter worth about $2,991,000. Marshall Wace LLP bought a new position in Oculis in the 4th quarter valued at about $914,000. Finally, Alyeska Investment Group L.P. boosted its holdings in shares of Oculis by 152.3% during the fourth quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock worth $6,617,000 after acquiring an additional 200,000 shares during the period. Institutional investors own 22.30% of the company’s stock.

Key Stories Impacting Oculis

Here are the key news stories impacting Oculis this week:

• Positive Sentiment: Company is actively presenting at multiple investor conferences in March and reiterated late‑stage pipeline milestones — Privosegtor received breakthrough therapy designation (optic neuritis), OCS‑01 topline readout expected in Q2 2026, and Licaminlimab advancing as a genotype‑driven program — supporting longer‑term upside for the stock. Oculis to Participate in Upcoming Investor Conferences
• Positive Sentiment: HC Wainwright raised a price target to $44 (published by AmericanBankingNews), which can provide technical/psychological support despite other model reductions. HC Wainwright Boosts Oculis Price Target
• Neutral Sentiment: Oculis filed its audited 2025 consolidated financial statements and MD&A on Form 20‑F — useful for diligence but largely informational unless the filings reveal unexpected surprises. Oculis Publishes 2025 Consolidated Financial Statements
• Neutral Sentiment: Company published notifications that RSUs granted to directors have vested and been settled — standard disclosure; could be neutral if shares are retained, or slightly negative if it leads to insider selling. Oculis Publishes Notifications of Transactions
• Negative Sentiment: Multiple analyst teams (LifeSci Capital and HC Wainwright) cut near‑term quarterly and FY2026 EPS forecasts, trimming expectations for Q1–Q4 and lowering FY numbers — these downward revisions increase near‑term earnings uncertainty and likely triggered selling pressure. (Analyst notes summarized on MarketBeat.) Analyst Estimate Reductions

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.